Read more
1:24 PM · 15 October 2025

Abbott reports no surprises in Q3, but tariff risks and lowered forecasts drag the share price down💡

Key takeaways
Key takeaways
  • Abbott reports Q3 results in line with forecasts
  • However, concerns about tariffs push share prices down ahead of Wall Street opening

Abbott (ABT.US) published a solid report for the third quarter of 2025, presenting results in line with market expectations, although the context surrounding the company was not free from tensions resulting from the threat of new trade tariffs from the Trump administration.

In Q3, Abbott reported adjusted earnings per share (EPS) of $1.30 and revenues of $11.4 billion, both in line with analyst consensus. Organic sales growth was 5.5% y/y, while sales in the Medical Devices segment grew by as much as 15%. The company reported a mixed annual EPS forecast of $5.12–5.18 (expected $5.15; the upper limit, which was $5.20, was lowered) and expects organic sales growth in 2025 to be 7.5-8% (excluding COVID-19 tests; 7.74% was expected).

Despite the figures being in line with forecasts, concerns about potential US tariffs on medical devices had a negative impact on the stock price, which fell by more than 4% before the opening of Wall Street sesion. At the same time, Abbott is not slowing down its investments in the US, expanding production and adapting to new regulatory challenges.

Abbott Q3 2025: Earnings, Sales & Outlook (XTB)

Abbott Q3 2025: earnings, sales, and forecasts. Source: XTB 

 

21 April 2026, 3:17 PM

UnitedHealth Group earnings: Healthy growth

21 April 2026, 3:04 PM

US Open: Macro Up, Tensions Down!

21 April 2026, 3:00 PM

Defense sector earnings: RTX, Thales and Northrop Grumman

20 April 2026, 4:57 PM

USA Rare Earth Acquires Key Brazilian Rare Earth Metal Mines ⛏️

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits